Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
Christina (Tina) P., CEO and Co-Founder of APS Foundation of America, shared on LinkedIn:
”Antiphospholipid Syndrome (APS) is an autoimmune disorder where your immune system mistakenly attacks proteins in your blood, making it clot more easily.
This can lead to serious health problems like blood clots in veins and arteries (deep vein thrombosis, pulmonary embolism), strokes, heart attacks, and repeated miscarriages or stillbirths.
It can affect anyone, though it’s more common in women and often diagnosed between ages 20 and 40.
Here’s why donating to the APS Foundation of America, Inc. is so important:
The APS Foundation of America is dedicated to supporting both adult and pediatric research into APS. In 2025, they awarded three $10,000 microgrants to research teams and $10,000 to ICAPA. They also aim to set aside 10% of donations for future research funding.
Education and Awareness: They provide vital information and education about APS to patients, their families, and the general community.
This includes information on diagnosis, symptoms, treatment, and coping.
They also work to raise national awareness for APS, which is the leading cause of stroke in young people and a significant factor in recurrent miscarriages.
The APS Foundation of America offers support and resources for those living with APS, including a network of doctors familiar with the condition and an online forum for communication with other patients.
They advocate for earlier diagnosis and better patient care.
Founded in 2005, the APS Foundation of America is a volunteer-run 501(c)(3) public charity.
They strive to keep administrative costs low, with many members being patients themselves.
They also aim for transparency, with a Charity Navigator score of 98% for accountability and finance.
Your donations help the APS Foundation of America continue its crucial work in fighting this often-misunderstood illness, advancing research, and supporting those affected.
Corporate Donations message us.”
Stay updated with Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026